Stock Analiz

Rockwell Medical, Inc. RMTI

Biotechnology: Pharmaceutical Preparations · IPO 1998 · data as of November 13, 2026

$7.03Market cap $28M
Open the interactive analysis →

Rockwell Medical, Inc. (RMTI) is a healthcare company listed in the US with a market value of about $28M. In the twelve months to September 30, 2026 it had revenue of $73M and net income of -$6M, a net margin of -7.8%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 33.7, 5-year revenue growth of 2% a year, a 5-year average ROIC of -33%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 29% below the current price.

About Rockwell Medical

Rockwell Medical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 1998. Revenue went from $54M in 2014 to $69M in 2025, growth of about 2.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 151% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF33.7
P/S0.4
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield3.0%
Shareholder yield0.0%
Intrinsic value vs. price−29%

Growth and quality

Revenue growth (1 yr)-31.8%
Revenue growth (5 yrs, per year)2.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-19.3%
ROIC (5-yr avg.)-32.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$73M$69M$101M$84M$73M$62M$62M$61M$63M$57M$53M
Net income-$6M-$5M-$480000-$8M-$19M-$33M-$31M-$34M-$32M-$26M-$20M
Free cash flow$828000-$1M$3M-$10M———————
EPS (diluted)$-0.07$-0.15$-0.03$-0.37$-1.31$-3.83$-4.51$-6.16$-6.71$-5.61$-4.29
Net margin-7.8%-7.7%-0.5%-10.1%-25.7%-52.8%-49.7%-55.7%-50.7%-45.2%-37.2%
ROIC—-9.7%1.4%-20.6%-48.5%-85.9%-39.3%-112.0%-94.0%-78.8%-30.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $20.00, 184% above the current price; targets range from $20.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-2.12 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Rockwell Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 29% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Rockwell Medical pay a dividend?

Not currently.

Is Rockwell Medical a good stock to buy?

We do not give buy or sell advice. Rockwell Medical scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.